Clinically: Surgical training with Professors K.Schwemmle (Giessen) and H.G.Beger (Ulm); APL Professor of Surgery at Univ.Ulm since 2001; Head of Dept.Surgery, of DKG large bowel organ center and DGAV center of expertise for the treatment of malignant peritoneal disease at APK Wiesbaden (1/2002-1/2018). Formation and head of the national research group FOGT. Improvement of 5-y-overall survival rate in colon cancer UICC III from 48% to 72%. Inaugural significant improvements in curative treatment of advanced metastatic disease. Fundamental analysis of factors determining quality in GI-cancer surgery. Leading positions at Ulm University and Asklepios Paulinen Hospital Wiesbaden. Foundation and Head Med.Board Surgery Asklepios 2002-2012. Member Boards of Trustees Asklepios Company; Head Arbitration Board Asklepios Company. Advisor to executive officers Asklepios. Chief Medical Officer Broermann Research GmbH. Scientfically: DFG funded postdoctoral training with Prof.Charles Heidelberger and J.Landolph at USC Kenneth Norris Cancer Center 1980-82; DFG funded translational research projects, honoreded with Schouder Award Lecture, Sackler School of Medicine, Tel Aviv University 2001, and Oscar Schubert Award and Lecture, Swedish Society of Medicine, Stockholm 2004; in vitro phase II trial and protocol development for regional chemotherapeutic procedures; first paper on treatment individualization of chemotherapy in nonresectable liver tumors/metastases using cell culture and molecular biology, awarded as “best paper of the year” in the journal “Cancer” (December 2000). Establishment of multimodal therapy of colon and rectal cancer in Germany with large scale phase III trials FOGT 1, 2, 4. First prospective randomized trial/paper proofing positive effect of treatment individualization in colorectal metastases with molecular TS determination (FOGT 5, cooperation with P.V.and K.Danenberg, LA, CA, USA). FOGT 1-5 involving nearly 3000 patients from 64 cooperating German hospitals. One of the first papers showing potential predictive effect of TS and DPDH determination in primary tumors treated with neoadjuvant/adjuvant multimodal therapy (FOGT 1+2, coop. with PV+K.Danenberg). First report on Split Time Resection (STR) of nonresectable colorectal liver metastasis (including treatment individualization). One of the two first reports with a major patient number on downstaging and secondary resection of primarily nonrectable colorectal liver metastases. Basic research and co-development of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) up to the S3 guide line level in Germany. Oral (original and review) presentations, organization and head of sessions (> 1000) in (frequently prestigious) conferences and publications (> 300) in (frequently highly) rated journals.        Societies: Member of the relevant national/international surgical and cancer research societies, leading positions. Member of DKG national S3 guide line commissions (colon- and rectal cancer, pancreatic cancer, psychooncology). Co-foundation of “du bist kostbar”, meanwhile a national DKG-project for cancer prevention. 1-year-action for secondary colonoscopic prevention of colon- and rectal cancer, theoretically savingtheoretically >150  lifes. Many national/international contacts with co-organization of meetings. Foundation and Head ICRCC (International Colon and Rectal Cancer Club), President of 12 ICRCC-Meetings worldwide. Married since 12/1980 (Santa Barbara; CA, USA) with Dr.oec.troph. Reinhild Link, happy family with the children Dr.phil.Dipl.psych.Daniela Link, 33y, Psychology/Economy, Univ.Lausanne/CH, Christian Link, 27y, Medical Doctor Semmelweis Univ.Budapest/ASM Hamburg Dmedical student, Asklepios-Semmelweis Medical School Budapest-Hamburg, and Carola Link, 26y, medical student, Univ.Heidelberg-Mannheim.